Desloratadine: An update of its efficacy in the management of allergic disorders

Drugs

Volumn 63, Issue 19, 2003, Pages 2051-2077

  Murdoch, David ^a   Goa, Karen L ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Chronic idiopathic urticaria (CIU); Desloratadine; H1 antihistamine; Histamine H1 receptor antagonist; Perennial allergic rhinitis (PAR); Pharmacodynamics; Pharmacokinetics; Seasonal allergic rhinitis (SAR); Therapeutic use

Indexed keywords

ANTIHISTAMINIC AGENT; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DESLORATADINE;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSMENORRHEA; EXPIRATORY FLOW RATE; FORCED EXPIRATORY FLOW; HUMAN; INSPIRATORY CAPACITY; MUSCLE FATIGUE; MYALGIA; PERENNIAL RHINITIS; PHARYNGITIS; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY; LORATADINE;

CITRUS X PARADISI; STAPHYLOCOCCUS PHAGE 3A;

EID: 0141637446     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363190-00010     Document Type: Review

References (122)

1. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma (ARIA): in collaboration with the World Health Organization. Allergy 2002; 57 (9): 841-55
2. Bachert C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 2002; 57 Suppl. 75: 13-8
3. 1-receptor anatagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Desloratadine Study Group. Clin Drug Invest 2001; 21 (1): 25-32
4. Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med 2002 Dec 16; 113 Suppl. 8: 17s-24s
5. Schering-Plough Corporation. Schering-Plough announces Clarinex (desloratadine) tablets approved for allergic rhinitis and chronic idiopathic urticaria. Media Rel Available from URL: http://www.schering-plough.com [Accessed 2002 Feb 12]
6. Negro-Álvarez JM, Miralles-López JC. Chronic idiopathic urticaria treatment. Allergol Immunopathol (Madr) 2001 Jul 31; 29 (4): 129-32
7. Ring J, Hein R, Gauger A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy 2001; 56 Suppl. 65: 28-32
8. Day J. Pros and cons of the use of antihistamines in managing allergic rhinitis. J Allergy Clin Immunol 1999 Mar; 103 Suppl. Pt 2: S395-9
9. Banfield C, Herron J, Keung A, et al. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002; 41 Suppl. 1: 37-44
10. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001 Jan; 40 (1): 72-6
11. Reichmuth D, Lockey RF. Present and potential therapy for allergic rhinitis: a review. Biodrugs 2000; 14 (6): 371-87
12. Scadding GK. Could treating asthma help rhinitis? Clin Exp Allergy 1997 Dec; 27: 1387-93
13. LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999 Mar; 103 Suppl. Pt 2: S388-94
14. McClellan K, Jarvis B. Desloratadine. Drugs 2001; 61 (6): 789-96; discussion 797
15. 1 receptor. Eur J Pharmacol 2002 Aug 9; 449 (3): 229-37
16. 1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. ArzneimittelForschung 2000 Apr; 50 (4): 345-52
17. DuBuske LM. Pharmacology of desloratadine: special characteristics. Clin Drug Invest 2002; 22 Suppl. 2: 1-11
18. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001 Sep; 31 (9): 1369-77
19. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995 Aug; 4 (Pt II): 272-6
20. Marone G, Genovese A, Granata A, et al. Pharmacological modulation of human mast cells and basophils. Clin Exp Allergy 2002; 32: 1682-9
21. Kowalski ML, Lewandowska A, Wozniak J, et al. Desloratadine inhibits calcium ionophore induced LTC4 generation by nasal polyp tissue [abstract no. 13]. Ann Allergy Asthma Immunol 2002 Jan; 88: 79
22. Lippert U, Möller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1 - and H2-receptor antagonists [published erratum appears in Exp Dermatol 2000; 9: front cover]. Exp Dermatol 2000; 9: 118-24
23. Agrawal DK, Berro A, Kreutner W, et al. Anti-inflammatory properties of desloratadine: effect on eosinophil chemotaxis, adhesion and release of superoxide anions [abstract]. J Allergy Clin Immunol 2000 Jan; 105 Pt 2: S16-7
24. Vignola AM, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995 Mar; 50 (3): 200-3
25. Papi A, Papadopoulos NG, Stanciu LA, et al. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001 Aug; 108 (2): 221-8
26. Wu R, Anthes JC, Kreutner W, et al. Desloratadine exhibits inverse agonism and inhibits NFkB activity [abstract no. 859]. J Allergy Clin Immunol 2003; 111 (2 Pt 2): S280
27. Cyr MM, Baatjes AJ, Hayes LM, et al. The effect of desloratadine on eosinophil/boasophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study [abstract]. J Allergy Clin Immunol 2002 Jan; 109 Suppl.: S117
28. Marshall GD, Henninger ED, Maniatis E, et al. Immuno-modulatory effects of desloratadine: changes in type-1/type-2 cytokine expression in PBMC cultures [abstract]. J Allergy Clin Immunol 2002 Jan; 109 Suppl.: S206-7
29. 1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. ArzneimittelForschung 2000 May; 50 (5): 441-8
30. + channels. J Cardiovasc Pharmacol 1997 Jul; 30 (1): 42-54
31. 1-receptor antagonist [abstract]. J Allergy Clin Immunol 2000 Jan; 105 Pt 2: S383
32. Handley DA, McCullough JR, Fang Y, et al. Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine [abstract no. P164]. The American College of Allergy, Asthma & Immunology 1996 Annual Meeting; 1996 Nov 8-13; Boston, 65
33. Cunningham D, Molnar C, Ellis J, et al. The effects of desloratadine on heart rate and blood pressure in anesthetized rats: evidence for potent antimuscarinic activity in vivo [abstract]. Ann Allergy Asthma Immunol 2001 Jan; 86: 85
34. Horak F, Stübner UP, Zieglmayer R, et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis [abstract no. 1000]. Allergy 2000; 55 Suppl. 63: 279
35. Horak F, Stübner P. Decongestant activity of desloratadine in controlled-allergen-exposure trials. Clin Drug Invest 2002; 22 Suppl. 2: 13-20
36. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002 Oct; 32 (10): 1504-9
37. Horak F, Stubner P, Zieglmeyer R, et al. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003 Jun; 58 (6): 481-5
38. Jalowayski AA, Meltzer EO, Harris AG. Desloratadine treatment improves nasal patency as measured objectively by high-resolution rhinomanometry in patients with seasonal allergic rhinitis [abstract no. 41 plus poster]. Presented at the American Academy of Allergy Asthma and Immunology 60th Anniversary Meeting; 2003 March 7-12; Denver (CO). J Allergy Clin Immunol 2003 Feb; 111 (2 Pt 2): S81
39. Horak F, Stübner UP, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002 Jun; 109 (6): 956-61
40. Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002 Oct; 89 (4): 413-8
41. Stuebner UP, Horak F, Zieglmeyer R, et al. Desloratadine reduces nasal congestion and other signs and symptoms of allergic rhinitis (AR) induced by house dust mite (HDM) allergen exposure in the Vienna challenge chamber [abstract no. 42 plus poster]. Presented at the American Academy of Allergy Asthma and Immunology 60th Anniversary Meeting; 2003 March 7-12; Denver (CO). J Allergy Clin Immunol 2003 Feb; 111 (2 Pt 2): S81
42. Deruaz CA, Berney M, Monnier E, et al. The early allergic phase is better controlled by levocetirizine than desloratadine in a nasal provocation test with grass pollen allergen [abstract no. 296]. J Allergy Clin Immunol 2003 Feb; 111 Suppl.: 143
43. Frossard N, Purohit A, Kovacs S, et al. Fexofenadine is superior to loratadine and desloratadine in onset of action of histamine-induced wheal and flare inhibition [abstract no. P34]. Ann Allergy Asthma Immunol 2003; 90: 124
44. Frossard N, Purohit A, Melac M, et al. Comparative activity of cetirizine 10mg and desloratadine 5mg on histamine-induced skin wheal and flare responses during 24 hours [abstract no. P25]. Ann Allergy Asthma Immunol 2003 Jan; 90 (1): 121
45. Banfield C, Cutler D, Shneyer L, et al. Desloratadine suppresses histamine- and allergen-induced cutaneous wheal and flare responses in allergic subjects during 6 months' treatment [abstract no. 666 plus poster]. Presented at the American Academy of Allergy Asthma and Immunology 60th Anniversary Meeting; 2003 March 7-12; Denver (CO). J Allergy Clin Immunol 2003 Feb; 111 (2 Pt 2): S235
46. McNeely W, Wiseman LR. Intranasal azelastine: a review of its efficacy in the management of allergic rhinitis. Drugs 1998 Jul; 56: 91-114
47. Scadding GK. Desloratadine in the treatment of nasal congestion in seasonal allergic rhinitis: preclinical and clinical evidence. Clin Drug Invest 2002; 22 Suppl. 2: 21-32
48. Skoner DP, Gentile DA, Gungor A, et al. The effects of desloratadine (DL) on the allergic inflammatory response of the nasal mucosa associated with seasonal allergic rhinitis (SAR): a nasal mucosal biopsy study (NMBX) [abstract no. 51]. Journal Allergy Clin Immunol 2003; 111 (2 Pt 2): S83
49. Hermes B, Prochazka A-K, Haas N, et al. Upregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999; 103: 307-14
50. DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999 Feb; 21 (2): 281-95
51. Banfield C, Padhi D, Glue P, et al. Electrocardiographic effects of multiple high doses of desloratadine [abstract]. J Allergy Clin Immunol 2000 Jan; 105 Pt 2: S383
52. Kay G. No sedation or performance impairment with desloratadine, a novel antihistamine [abstract]. Ann Allergy Asthma Immunol 2001 Jan; 86: 84
53. Ridout F, Meadows R, Johnsen S, et al. Effects of desloratadine 5, 10 and 20 mg, and promethazine 25 mg on cognitive and psychomotor performance [abstract no. P35]. Ann Allergy Asthma Immunol 2003 Jan; 90 (1): 124
54. Wilken J, Kane R. Vigilance and cognitive functioning during treatment of seasonal allergic rhinitis (SAR): a comparison of diphenhydramine and desloratadine [abstract]. J Allergy Clin Immunol 2002 Jan; 109 Suppl.: S101
55. Schering-Plough. Data on file. 2003 May 14
56. Satish U, Streufert S, Dewan M, et al. Improved productivity in patients with seasonal allergic rhinitis: impact of desloratadine [abstract no. P28]. Ann Allergy Asthma Immunol 2003 Jan; 90 (1): 122
57. Hughes K, Craig T, Mende C, et al. The effect of desloratadine on sleep and daytime somnolence in subjects with allergic rhinitis [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 Suppl. Pt 2: A192
58. Scharf M, Rikken G, Salmun L, et al. Comparative effects of desloratadine and placebo with and without alcohol on performance measures [abstract]. J Allergy Clin Immunol 2000 Jan; 105 Pt 2: S394
59. The European Agency for the Evaluation of Medicinal Products. Scientific Discussion: Aerius [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/aerius/aerius.htm [Accessed 2003 Apr 9]
60. Affrime M, Gupta S, Banfield C, et al. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002; 41 Suppl. 1: 13-9
61. Gupta S, Banfield C, Affrime M, et al. Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin Pharmacokinet 2002; 41 Suppl. 1: 1-6
62. Affrime M, Banfield C, Gupta S, et al. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin Pharmacokinet 2002; 41 Suppl. 1: 21-8
63. Anonymous. Desloratadine (3543). 2003 Mosby's Drug Consult Available from URL: http://www.mosbydrugs.com [Accessed 2003 Jan 15]
64. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56 Suppl. 65: 7-13
65. Limon L, Kockler DR. Desloratadine: a nonsedating antihistamine. Ann Pharmacother 2003 Feb; 37 (2): 237-46
66. Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002; 41 (4): 311-8
67. Banfield C, Gupta S, Affrime M, et al. Pharmacokinetic equivalence of pediatric dosages of desloratadine syrup in children and standard 5-mg desloratadine tablets in adults [abstract no. 278 plus poster]. Presented at the American Academy of Allergy Asthma and Immunology 58th Annual Meeting; 2002 March 1-6; New York. J Allergy Clin Immunol 2002 Jan; 109 Suppl.: S103
68. Schering Corporation. Clarinex (desloratadine) tablets, reditabs tablets [online]. Available from URL: http://www.clarinex.com [Accessed 2003 Apr 29]
69. Barecki ME, Casciano CN, Johnson WW, et al. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos 2001 Sep; 29 (9): 1173-5
70. Wang E-J, Casciano CN, Clement RP, et al. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 2001 Aug; 29 (8): 1080-3
71. Favreau LV, Johnson WW, Chu A, et al. Desloratadine is not transported by human organic anion transport polypeptide-A [abstract no. P29]. Ann Allergy Asthma Immunol 2003 Jan; 90 (1): 122
72. Gupta S, Banfield C, Affrime M, et al. Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet 2002; 41 Suppl. 1: 7-12
73. Banfield C, Hunt T, Reyderman L, et al. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002; 41 Suppl. 1: 29-35
74. Banfield C, Gupta S, Kantesaria B, et al. No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine [abstract]. J Allergy Clin Immunol 2001 Feb; 107 Suppl.: S161
75. Khalilieh K, Krishna G, Marino M, et al. Lack of an interaction with coadministration of desloratadine and cimetidine [abstract]. Ann Allergy Asthma Immunol 2002 Jan; 88: 110
76. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001 Mar; 23 (3): 451-66
77. Bachert C, Virchow Jr CJ, Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: Results of a large observational study. Clin Drug Invest 2002; 22 Suppl. 2: 43-52
78. Kerney DL. Real world treatment with desloratadine in SAR patients [abstract no. P32]. Ann Allergy Asthma Immunol 2003 Jan; 90 (1): 123
79. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam Pract 2002 Aug 5; 3 (1): 14
80. Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc 2002 Sep 31; 23: 325-30
81. Meltzer EO, Harris AG. Desloratadine 5mg once daily significantly improves individual and total symptoms compared with placebo in patients with seasonal allergic rhinitis [abstract no. 61 plus poster]. Presented at the American Academy of Allergy Asthma and Immunology 60th Anniversary Meeting; 2003 March 7-12; Denver (CO). J Allergy Clin Immunol 2003; 111 (2 Pt 2): S86
82. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Desloratadine Study Group. Ann Allergy Asthma Immunol 2002 Nov; 89 (5): 485-91
83. Simons FER, Prenner BM, Finn Jr A. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003 Mar; 111 (3): 617-22
84. Kim KT, Sussman GL, Hebert J, et al. Effect of once-daily desloratadine in patients with perennial allergic rhinitis (PAR): a double-blind, placebo-controlled study [abstract no. 25 plus poster]. Presented at the American Academy of Allergy Asthma and Immunology 60th Anniversary Meeting; 2003 March 7-12; Denver (CO). J Allergy Clin Immunol 2003; 111 (2 Pt 2): S76
85. Monroe E, Finn A, Patel P. et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003 Apr; 48 (4): 535-41
86. Ring J, Gauger A, Hein R. Clinical efficacy of desloratadine in chronic urticaria. Clin Drug Invest 2002; 22 Suppl. 2: 33-41
87. Kapp A, Plenker A. Impact of desloratadine on signs, symptoms, and quality of life measures of chronic idiopathic urticaria (CIU) in clinical practice [abstract no. 1127]. J Allergy Clin Immunol 2003; 111 (2 Pt 2): S349
88. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001 Nov; 56 (11): 1077-80
89. Schmier J, Leidy N, Prasad M. Health-related quality of life outcomes of desloratadine in patients with moderate-to-severe SAR [abstract]. Ann Allergy Asthma Immunol 2001 Jan; 86: 111
90. Corren J, Salmun LM. Quality of life in patients with seasonal allergic rhinitis is improved by desloratadine [abstract no. 676 plus poster]. Presented at the XIXth Congress of the European Academy of Allergology and Clinical Immunology; 2000 July 1-5; Lisbon. Allergy 2000; 55 Suppl. 63: 191
91. Nayak A, Lorber R, Salmun LM. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 2000 Jan; 105 Pt 2: S384
92. Nathan R. Desloratadine relieved nasal congestion in patients with seasonal allergic rhinitis and concurrent asthma [abstract]. Desloratadine Study Group. Ann Allergy Asthma Immunol 2001 Jan; 86: 84
93. Berger WE. Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma [abstract plus poster]. Desloratadine Study Group. J Allergy Clin Immunol 2001 Feb; 107 Suppl.: S162
94. Ratner PH. Desloratadine improved asthma symptoms and reduced bronchodilator use in 2 studies of patients with asthma and SAR [abstract]. Desloratadine Study Group. Ann Allergy Asthma Immunol 2001 Jan; 86: 109
95. 1 ≤80% [abstract]. Desloratadine Study Group. Am J Respir Crit Care Med 2001 Apr; 163 Suppl. Pt 2: A189
96. Bloom M, Herron J, Staudinger H. Desloratadine syrup is safe and well tolerated in chidlren with allergic rhinitis and chronic idiopathic urticaria [abstract]. Ann Allergy Asthma Immunol 2002 Jan; 88: 79
97. Borchard UHJ, Daly AF, Plenker A. Desloratadine: safety and tolerability data in clinical practice [abstract no. 17]. J Allergy Clin Immunol 2003; 111 (2 Pt 2): S74
98. Schering Corporation. Data on file. 2003 Jul 11
99. The European Agency for the Evaluation of Medicinal Products. Summary of product characteristics: Neoclarityn [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/neoclaratyn/neoclaratynM.htm [Accessed 2003 Apr 9]
100. Pharmacos. Pharmaceuticals: Community register of medicinal products for human use [online]. Available from URL: http://pharmacos.eudra.org/F2/register/alfregister.htm [Accessed 2003 Apr 9]
101. The European Agency for the Evaluation of Medicinal Products. Package leaflet: Allex [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/allex/allex.htm [Accessed 2003 Apr 9]
102. The European Agency for the Evaluation of Medicinal Products. Package leaflet: Aerius [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/aerius/aeriusM.htm [Accessed 2003 Apr 9]
103. The European Agency for the Evaluation of Medicinal Products. Package leaflet: Opulis [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/Opulis/OpulisM.htm [Accessed 2003 Apr 9]
104. The European Agency for the Evaluation of Medicinal Products. Package leaflet: Neoclarityn [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/neoclaratyn/neoclaratynM.htm [Accessed 2003 Apr 9]
105. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products December 2002 plenary meeting monthly report [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pr/624802en.pdf [Accessed 2003 Apr 29]
106. The European Agency for the Evaluation of Medicinal Products. Package leaflet: Azomyr [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/azomyr/azomyrM.htm [Accessed 2003 Apr 9]
107. Mackay IS, Durham SR. Perennial rhinitis. BMJ 1998 Mar 21; 316: 917-20
108. Lemanske Jr RF. A review of the current guidelines for allergic rhinitis and asthma. J Allergy Clin Immunol 1998 Feb; 101 Pt 2: S392-6
109. Hein R. Chronic urticaria: impact of allergic inflammation. Allergy 2002; 57 Suppl. 75: 19-24
110. Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs 2002 Feb; 11 (2): 259-73
111. Horak F, Stübner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10mg o.d. and fexofenadine 120mg o.d. in reducing symptoms of seasonal allergic rhinits. Int Arch Allergy Immunol 2001; 125: 73-9
112. DuBuske LM. Mediator antagonists in the treatment of allergic disease. Allergy Asthma Proc 2001 Sep 31; 22 (5): 261-75
113. Mincarini M, Pasquali M, Cosentino C, et al. Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives. Pulm Pharmacol Ther 2001; 14 (4): 267-76
114. Beckman DB, Grammer LC. Pharmacotherapy to prevent the complications of allergic rhinitis. Allergy Asthma Proc 1999 Jul 31; 20: 215-23
115. Simons FER. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999 Sep; 104: 534-40
116. Wilson AM. Are antihistamines useful in managing asthma? Curr Opin Allergy Clin Immunol 2002 Feb; 2 (1): 53-9
117. Grant JA, Nicodemus CF, Findlay SR, et al. Certrizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995; 95 (5 Pt 1): 923-32
118. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of laratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100 (6 Pt 1): 781-8
119. Monroe EW, Daly AF, Shaloub RF. Appraisal of the vailidity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997; 99 (2): S798-806
120. Bousquest J, Czarlewski W, Cougnard J, et al. Changes in skin test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis. Allergy 1998; 53: 579-85
121. Bousquet J, Van Cauwenberge P, Bachert C. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI) Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003; 58: 192-7
122. Tedeschi A, Airaghi L, Lorini M, et al. Chronic urticaria: a role for newer immunomodulatory drugs? Am J Clin Dermatol 2003; 4 (5): 297-305